

- **Name:** Hyeon-Su Im, MD
  - **Current Position & Affiliation:** Assistant Professor, Division of Hematology and Oncology, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine
  - **Country:** Korea
- 

**• Educational Background:**

M.D., Hanyang University College of Medicine, 2011

M.Sc., University of Ulsan Graduate School of Medicine, 2019

**• Professional Experience:**

Internship, Asan Medical Center (Mar 2011 – Feb 2012)

Residency in Internal Medicine, Asan Medical Center (May 2015 – Feb 2019)

Clinical Fellow in Medical Oncology, Asan Medical Center (Mar 2019 – Feb 2020)

Assistant Professor, Division of Hematology and Oncology, Ulsan University Hospital (Mar 2020 – Aug 2021)

Associate Professor, Division of Hematology and Oncology, Ulsan University Hospital (Sep 2021 – Present)

**• Professional Organizations:**

The Korean Association of Internal Medicine

The Korean Cancer Association

Korean Society of Medical Oncology (KSMO)

Korean Cancer Study Group (KCSG)

The Korean Gastric Cancer Association

American Society of Clinical Oncology (ASCO)

European Society for Medical Oncology (ESMO)

**• Main Scientific Publications:**

1. Sin C, Kim H, Im HS, Ock M, Koh SJ. Development and pilot study of "Smart Cancer Care": a platform for managing side effects of chemotherapy. BMC Health Serv Res. 2023 Aug 29;23(1):922.
2. Sin C, Lee DY, Kim H, Im HS, Koh SJ, Kang DY. Effectiveness of self-reported management program of cancer patients. Digit Health. 2024 Jul 23;10:20552076241253090.
3. Im HS, Lee I, Kim S, Lee JS, Kim JH, Moon JY, Park BK, Lee KH, Lee MA, Han S, Hong Y, Kim H, Cheon J, Koh SJ. Experience and perspectives of end-

- of-life care discussion and physician orders for life-sustaining treatment of Korea (POLST-K): a cross-sectional study. *BMC Med Ethics*. 2023 Mar 7;24(1):18.
4. Kim HD, Im HS, Kim JH, Jeong H, Yoon SK, Park I, Lee JL. Use of Gemcitabine plus Carboplatin is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5. *Cancer Res Treat*. 2021 Oct;53(4):1166-1173.
  5. Jeong H, Im HS, Kim W, Lee JS, Song SY, Song JS, Cho KJ, Chung HW, Lee MH, Kim JE, Ahn JH. Demographics, Changes in Treatment Patterns, and Outcomes of Bone and Soft Tissue Sarcomas in Korea-A Sarcoma-Specific, Institutional Registry-Based Analysis. *Cancer Manag Res*. 2021 Nov 24;13:8795-8802.
  6. Cheon J, Im HS, Shin HJ, Kim I, Lee WS, Lee KH, Park SK, Kim MK, Choi UJ, Kim JH, Lee I, Jo JC. Pegteograstim prophylaxis for chemotherapy-induced neutropenia and febrile neutropenia: a prospective, observational, postmarketing surveillance study in Korea. *Support Care Cancer*. 2021 Sep;29(9):5383-5390.
  7. Jeong H, Im HS, Bang Y, Kim YH, Kim HR, Lee HJ, Jung HY, Lee GH, Song HJ, Kim DH, Choi KD, Lee JH, Ahn JY, Na HK, Ryu JS, Kang J, Kim SB, Kim JH, Park SR. Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma. *Cancer Med*. 2021 Mar;10(5):1745-1758.
  8. Kim EJ, Im HS, Lee J, Cho EH, Kim YH, Kim HR, Kim JH, Park SR. Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy. *Curr Probl Cancer*. 2021 Jun;45(3):100685.
  9. Yoo C, Im HS, Kim KP, Oh DY, Lee KH, Chon HJ, Kim JH, Kang M, Kim I, Lee GJ, Oh SY, Choi Y, Choi HJ, Kim ST, Park JO, Ryoo BY. Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. *Ther Adv Med Oncol*. 2019 Aug 23;11:1758835919871126.